Literature DB >> 15501813

In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists.

Govindarajan Rajagopalan1, Moon M Sen, Chella S David.   

Abstract

Superantigen peptide antagonists failed to block T-cell activation and cytokine production as well as toxic shock induced by staphylococcal enterotoxin B (SEB) in HLA class II transgenic mice. They also failed to inhibit the binding of SEB to HLA class II molecules as well as activation of human T lymphocytes in vitro.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15501813      PMCID： PMC522998          DOI： 10.1128/IAI.72.11.6733-6737.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  18 in total

1.  Inhibition of bacterial superantigens by peptides and antibodies.

Authors:  K Visvanathan; A Charles; J Bannan; P Pugach; K Kashfi; J B Zabriskie
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.

Authors:  G Arad; R Levy; D Hillman; R Kaempfer
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 3.  Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents.

Authors:  J M Madsen
Journal:  Clin Lab Med       Date:  2001-09       Impact factor: 1.935

Review 4.  Toxic shock syndrome and bacterial superantigens: an update.

Authors:  J K McCormick; J M Yarwood; P M Schlievert
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

5.  Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock.

Authors:  G Arad; D Hillman; R Levy; R Kaempfer
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

6.  A defect in central tolerance in NOD mice.

Authors:  H Kishimoto; J Sprent
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

7.  Enhanced susceptibility to superantigen-associated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice.

Authors:  S Sriskandan; M Unnikrishnan; T Krausz; H Dewchand; S Van Noorden; J Cohen; D M Altmann
Journal:  J Infect Dis       Date:  2001-06-15       Impact factor: 5.226

8.  Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock.

Authors:  R S Yeung; J M Penninger; T Kündig; W Khoo; P S Ohashi; G Kroemer; T W Mak
Journal:  Eur J Immunol       Date:  1996-05       Impact factor: 5.532

9.  Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines.

Authors:  Luis DaSilva; Brent C Welcher; Robert G Ulrich; M Javad Aman; Chella S David; Sina Bavari
Journal:  J Infect Dis       Date:  2002-05-23       Impact factor: 5.226

Review 10.  Superantigen antagonist peptides.

Authors:  M Llewelyn; J Cohen
Journal:  Crit Care       Date:  2001-02-26       Impact factor: 9.097
View more
  28 in total

1.  Endogenous superantigens shape response to exogenous superantigens.

Authors:  Govindarajan Rajagopalan; Manisha Singh; Moon M Sen; Narayana S Murali; Karl A Nath; Chella S David
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Acute systemic immune activation following conjunctival exposure to staphylococcal enterotoxin B.

Authors:  Govindarajan Rajagopalan; Michele K Smart; Robin Patel; Chella S David
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

3.  Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock.

Authors:  Teresa Krakauer; Marilyn Buckley
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.

Authors:  Govindarajan Rajagopalan; Ashenafi Y Tilahun; Yan W Asmann; Chella S David
Journal:  Physiol Genomics       Date:  2009-03-31       Impact factor: 3.107

5.  Passive therapy with humanized anti-staphylococcal enterotoxin B antibodies attenuates systemic inflammatory response and protects from lethal pneumonia caused by staphylococcal enterotoxin B-producing Staphylococcus aureus.

Authors:  Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan
Journal:  Virulence       Date:  2016-12-07       Impact factor: 5.882

6.  Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site.

Authors:  Tian Xia; Shuaiyi Liang; Huajing Wang; Shi Hu; Yuna Sun; Xiaojie Yu; Jun Han; Jun Li; Shangjing Guo; Jianxin Dai; Zhiyong Lou; Yajun Guo
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

7.  Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock.

Authors:  Avanish K Varshney; Xiaobo Wang; Emily Cook; Kaushik Dutta; Matthew D Scharff; Michael J Goger; Bettina C Fries
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

8.  Bacillus anthracis edema toxin inhibits Staphylococcus aureus enterotoxin B effects in vitro: a potential protein therapeutic?

Authors:  Teresa Krakauer; Stephen F Little; Bradley G Stiles
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

9.  Human leukocyte antigen class II transgenic mouse model unmasks the significant extrahepatic pathology in toxic shock syndrome.

Authors:  Ashenafi Y Tilahun; Eric V Marietta; Tsung-Teh Wu; Robin Patel; Chella S David; Govindarajan Rajagopalan
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 10.  Models matter: the search for an effective Staphylococcus aureus vaccine.

Authors:  Wilmara Salgado-Pabón; Patrick M Schlievert
Journal:  Nat Rev Microbiol       Date:  2014-07-07       Impact factor: 60.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.